Sweden. Elekta AB
| Date of agreement: | 27 Mar 2017 |
|---|---|
| Country: | Sweden |
| Customer: | Elekta AB |
| Amount in GBP: | GBP 90 million |
| Amount in EUR: | EUR 104.2 million |
| Maturity: | 5 years |
| NACE sector / loan type: | Research and development |
Project
The loan has been provided to finance R&D investments in the field of medical capital goods during 2016–2020. Elekta’s research programme focuses on the development of equipment and software for the treatment of cancers and brain disorders by means of radiotherapy.
This includes the development of new technology for improved quality of diagnostic images of tumours and more precise targeting of cancerous tissue during radiation therapy. Elekta operates several research centres worldwide, including in Sweden and Finland.
Elekta AB develops clinical solutions and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as medical software solutions. The company’s products are utilised in over 6,000 hospitals worldwide. Elekta is headquartered in Stockholm, Sweden, and employs around 3,600 people globally.
Fulfilment of NIB's mandate
Elekta’s annual R&D investments account for approximately 10% of total net sales, and are expected to increase further in the coming years, which will benefit R&D centres in Sweden and Finland. The research Elekta will conduct is likely to change the current standard of care for cancer patients by improving the precision of radiation delivery.
Sustainability summary
No sustainability issues are expected to result from the project.
